Final Countdown To St. Jude Acquisition – Abbott Scores US Antitrust Approval

Abbott has scored US FTC antitrust approval for its proposed $25bn acquisition of St. Jude. The approval comes with two conditions: that Abbott divests the vascular closure device and steerable sheath businesses to Terumo, and that it notifies the FTC if it intends to acquire lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
• Source: Shutterstock

Abbott Laboratories Inc.hascleared another significant hurdle in its effort to acquireSt. Jude Medical Inc. with the US antitrust watchdog, the Federal Trade Commission, giving conditional approval to the deal. Abbott is now in the final stages of completing its $25bn acquisition of St. Jude.

One of the conditions imposed by the FTC – and to which Abbott has agreed – has not come as...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

More from Business